Addario Lung Cancer Medical Institute

Prana Thoracic Announces Series A Financing

Retrieved on: 
Thursday, March 2, 2023

Prana Thoracic, Inc. (“Prana” or the “Company”), a medical device company developing the first minimally invasive lung tissue excision tool for early intervention in lung cancer, has announced the closing of a $3 million founding Series A financing led by New World Angels.

Key Points: 
  • Prana Thoracic, Inc. (“Prana” or the “Company”), a medical device company developing the first minimally invasive lung tissue excision tool for early intervention in lung cancer, has announced the closing of a $3 million founding Series A financing led by New World Angels.
  • The Series A funds and a previously announced $3M award from the Cancer Prevention & Research Institute of Texas will be used for product development and to support the Company’s first-in-human clinical studies.
  • “Our technology provides a definitive answer to patients with lung nodules and allows physicians to intervene earlier in the lung cancer patient’s journey,” said Joanna Nathan, CEO, and co-founder of Prana.
  • Prana’s technology was developed on the Texas Medical Center campus, in collaboration with Precision Thoracic Corporation.

North America AI In Cancer Diagnostics Market Report 2022: Ability to Make Diagnoses Without Professional Radiologists Boosts Sector - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023

The new AI-featured algorithms have overpassed the abilities of professional radiologists by allowing the forecast of patient reports utilizing MRI.

Key Points: 
  • The new AI-featured algorithms have overpassed the abilities of professional radiologists by allowing the forecast of patient reports utilizing MRI.
  • However, advanced AI methods can be employed to discover the gene mutations from tumor pathology images rather than utilizing standard genomic sequencing.
  • There were 863,830 female cases and 888,905 male cases of new invasive cancer recorded in the United States in 2019.
  • The US market dominated the North America AI In Cancer Diagnostics Market by Country in 2021; thereby, achieving a market value of $146.7 million by 2028.

New Study to Address Cancer Treatment Resistance for People Who Are KRAS Positive

Retrieved on: 
Wednesday, November 30, 2022

"The development of treatment resistance is unfortunately common in patients with lung cancers and other tumor types with the KRAS G12C mutation," said Dr. Awad.

Key Points: 
  • "The development of treatment resistance is unfortunately common in patients with lung cancers and other tumor types with the KRAS G12C mutation," said Dr. Awad.
  • "Treatment resistance is a harsh reality for too many people with lung cancer," said Richard Erwin, executive director of clinical operations at ALCMI.
  • SPARK Study blood samples will be analyzed to help advance research and treatment for KRAS-positive lung cancer.
  • "The SPARK study will research why KRAS-mutant cancers develop drug resistance, which will then fuel research into preventing and overcoming resistance.

KRAS Kickers Give Cancer the Boot!

Retrieved on: 
Wednesday, September 28, 2022

CHARLOTTE, N.C., Sept. 28, 2022 /PRNewswire/ -- Cancer patient advocates, doctors, researchers, and pharmaceutical industry partners are joining forces during KRAS Kickers Connect conference Sept. 30-Oct. 1 in Charlotte. The in-person and virtual hybrid event features world renowned scientists and patient advocate leaders. KRAS Kickers Connect will be held Friday and Saturday at the Hyatt Centric Charlotte SouthPark, 3100 Apex Dr., Charlotte.

Key Points: 
  • CHARLOTTE, N.C., Sept. 28, 2022 /PRNewswire/ -- Cancer patient advocates, doctors, researchers, and pharmaceutical industry partners are joining forces during KRAS Kickers Connect conference Sept. 30-Oct. 1 in Charlotte.
  • KRAS Kickers Connect will be held Friday and Saturday at the Hyatt Centric Charlotte SouthPark, 3100 Apex Dr., Charlotte.
  • "For decades, KRAS-driven cancers were considered 'undruggable,'" says Terri Conneran, KRAS Kickers Founder and Charlotte lung cancer patient.
  • Conneran, who has been battling lung cancer since 2017, founded KRAS Kickers to create a network for patients and families in search of KRAS information and support.

OncoHost Welcomes UC Davis Professor, David Gandara, M.D., to Scientific Advisory Board

Retrieved on: 
Tuesday, November 30, 2021

"We are thrilled to have Prof. Gandara, an award-winning researcher and physician, join the OncoHost team.

Key Points: 
  • "We are thrilled to have Prof. Gandara, an award-winning researcher and physician, join the OncoHost team.
  • "His clinical and scientific impact in the field of developing predictive biomarkers for therapeutic efficacy will be invaluable to OncoHost's approach, and we look forward to growing together."
  • "I am delighted to join OncoHost's scientific advisory boardat such an exciting time in the company's development, including the upcoming launch of its host response profiling platform, PROphet," said Prof. Gandara.
  • OncoHost combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy.

New Study Seeks Origins of Young Lung Cancer

Retrieved on: 
Tuesday, February 23, 2021

SAN CARLOS, Calif. and WASHINGTON, Feb. 23, 2021 /PRNewswire/ -- Continuing their collaboration to transform lung cancer survival and to accelerate novel research advancements for people with lung cancer, the Addario Lung Cancer Medical Institute (ALCMI) and GO2 Foundation for Lung Cancer (GO2 Foundation) are building upon prior research efforts by launching a new study to gain a better understanding of the underlying cause(s) of lung cancer diagnosed in young people under the age of 40.

Key Points: 
  • SAN CARLOS, Calif. and WASHINGTON, Feb. 23, 2021 /PRNewswire/ -- Continuing their collaboration to transform lung cancer survival and to accelerate novel research advancements for people with lung cancer, the Addario Lung Cancer Medical Institute (ALCMI) and GO2 Foundation for Lung Cancer (GO2 Foundation) are building upon prior research efforts by launching a new study to gain a better understanding of the underlying cause(s) of lung cancer diagnosed in young people under the age of 40.
  • The Epidemiology of Young Lung Cancer (EoYLC) study follows on ALCMI's earlier groundbreaking Genomics of Young Lung Cancer (GoYLC) study.
  • Now that we have confirmed that young lung cancer looks different than other lung cancer, discovering the how and why of it through epidemiology will be critical to our ongoing efforts to prevent, diagnose early, and more effectively treat lung cancer in young patients.
  • What we learn from young lung cancer will also help unlock answers for the entire lung cancer community," said Bonnie J. Addario, GO2 Foundation co-founder, board chair, and Stage IIIB lung cancer survivor.

Lung Cancer Screening Awareness Campaign Focuses on At-Risk Kentuckians

Retrieved on: 
Monday, June 10, 2019

LEXINGTON, Ky., June 10, 2019 /PRNewswire/ -- GO2 Foundation for Lung Cancer (formerly known as Lung Cancer Alliance and the Bonnie J. Addario Lung Cancer Foundation) is conducting a statewide education campaign in partnership with the University of Kentucky bringing lung cancer screening awareness to the thousands of Kentuckians at risk for the disease.

Key Points: 
  • LEXINGTON, Ky., June 10, 2019 /PRNewswire/ -- GO2 Foundation for Lung Cancer (formerly known as Lung Cancer Alliance and the Bonnie J. Addario Lung Cancer Foundation) is conducting a statewide education campaign in partnership with the University of Kentucky bringing lung cancer screening awareness to the thousands of Kentuckians at risk for the disease.
  • The campaign stems from the Kentucky LEADS Collaborative (Lung Cancer, Education, Awareness, Detection, Survivorship), a project led by the University of Kentucky (UK), University of Louisville (UofL), and the GO2 Foundation for Lung Cancer.
  • As part of the Kentucky LEADS effort to reduce lung cancer in the state, educational ads are airing in cable television markets throughout the state, urging current and former heavy smokers 55 years and older to talk to a clinician about lung cancer screening.
  • Founded by patients and survivors, GO2 Foundation for Lung Cancer (a merger between Lung Cancer Alliance and the Bonnie J. Addario Lung Cancer Foundation) transforms survivorship as the world's leading organization dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer.

The Nation's Leading Lung Cancer Organizations Join Forces to Launch "GO2 Foundation for Lung Cancer"

Retrieved on: 
Monday, April 8, 2019

SAN CARLOS, Calif. and WASHINGTON, April 8, 2019 /PRNewswire/ --Two of the most effective and influential nonprofit organizations serving the lung cancer community, the Bonnie J. Addario Lung Cancer Foundation (ALCF) and Lung Cancer Alliance (LCA) today proudly announced they are joining forces as the GO2Foundation for Lung Cancer.

Key Points: 
  • SAN CARLOS, Calif. and WASHINGTON, April 8, 2019 /PRNewswire/ --Two of the most effective and influential nonprofit organizations serving the lung cancer community, the Bonnie J. Addario Lung Cancer Foundation (ALCF) and Lung Cancer Alliance (LCA) today proudly announced they are joining forces as the GO2Foundation for Lung Cancer.
  • "We are thrilled to blend our talent, resources, commitment and compassion to create this powerhouse foundation," said Bonnie J. Addario, lung cancer survivor, Co-Founder and Chair of the Board of Directors of the GO2Foundation for Lung Cancer, and most recently Founder and Chair of ALCF.
  • "The GO2 Foundationwill transform what it means to live with lung cancer and increase the patient survival rate of the world's number one cancer killer annually.
  • "Like Skip, who always inspired his team to be strategic and think big, GO2 Foundation embraces this same spirit to make the most profound impact ever on lung cancer survival.

Bonnie J. Addario Lung Cancer Foundation's Simply the Best Dinner and Gala Honors Those Working on the Front Lines to Fight Lung Cancer

Retrieved on: 
Monday, November 19, 2018

"When we held our first gala 13 years ago, our hopes of turning lung cancer into a chronic, manageable disease seemed like a far-distant dream," said Bonnie J. Addario, 14-year lung cancer survivor and ALCF founder.

Key Points: 
  • "When we held our first gala 13 years ago, our hopes of turning lung cancer into a chronic, manageable disease seemed like a far-distant dream," said Bonnie J. Addario, 14-year lung cancer survivor and ALCF founder.
  • The Simply the Best Dinner and Gala is ALCF's largest annual fundraising event.
  • More information about the 13th annual Simply the Best Dinner and Gala is available here .
  • The Bonnie J. Addario Lung Cancer Foundation (ALCF) is one of the largest international philanthropies (patient-founded, patient-focused and patient-driven) devoted exclusively to eradicating lung cancer through research, early detection, education and treatment.

Bonnie J. Addario Lung Cancer Foundation Announces Recipients of the Young Innovators Team Awards for Lung Cancer Research

Retrieved on: 
Wednesday, November 7, 2018

SAN CARLOS, Calif., Nov. 7, 2018 /PRNewswire/ --Today the Bonnie J. Addario Lung Cancer Foundation (ALCF) and the Van Auken Private Foundation (VAPF) announced the recipients of the ALCF-VAPF Young Innovators Team Awards (YITA).

Key Points: 
  • SAN CARLOS, Calif., Nov. 7, 2018 /PRNewswire/ --Today the Bonnie J. Addario Lung Cancer Foundation (ALCF) and the Van Auken Private Foundation (VAPF) announced the recipients of the ALCF-VAPF Young Innovators Team Awards (YITA).
  • "YITA supports the research of talented young doctors and scientists who are dedicated to finding a cure for the world's deadliest cancer," said Bonnie J. Addario, 14-year lung cancer survivor and ALCF founder.
  • Combining their expertise in lung cancer immunology and synthetic biology, the investigators will design probiotic bacterial strains that find and attack lung cancer.
  • The Bonnie J. Addario Lung Cancer Foundation (ALCF) is one of the largest international philanthropies (patient-founded, patient-focused and patient-driven) devoted exclusively to eradicating lung cancer through research, early detection, education and treatment.